Women at high bleeding risk (HBR) do not seem to experience more ischemic or bleeding events than men and may especially benefit from a regimen of short dual antiplatelet therapy (DAPT) after PCI, ...
PARIS, France—One month of dual antiplatelet therapy (DAPT) after PCI using contemporary stents not only is associated with similar rates of adverse clinical outcomes compared with 3 months or more in ...
Select high bleeding risk (HBR) patients can safely receive just 1 or 3 months of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) without more ischemic events, ...
In acute coronary syndrome (ACS), a prasugrel (Effient)-based antiplatelet regimen passed muster for reducing bleeding without compromising ischemic protection after percutaneous coronary intervention ...
A short-term course of dual antiplatelet therapy (DAPT) is non-inferior to a longer course in patients who have undergone placement of a particular kind of drug-eluting stent (DES), researchers ...
While dual antiplatelet therapy (DAPT) has long been the standard of care for the management of acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI), there is an ...
The first four patients were enrolled by (Professor Barbara Stähli and her team at the University Hospital of Zurich in Switzerland initiating the much awaited RCT which will assess the different ...
SAN FRANCISCO -- For ticagrelor-based antithrombotic regimens after drug-eluting stent implantation for acute coronary syndrome (ACS), stopping aspirin within the first month appeared to be safer than ...
BARCELONA, SPAIN — The European Society of Cardiology has issued a new "focused update" on its guidelines on dual antiplatelet therapy (DAPT)—aspirin plus a P2Y 12 inhibitor—in coronary artery disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results